Potential therapeutic agents against COVID-19: What we know so far
2020; Lippincott Williams & Wilkins; Volume: 83; Issue: 6 Linguagem: Inglês
10.1097/jcma.0000000000000318
ISSN1728-7731
AutoresChih-Chia Lu, Mei‐Yu Chen, Wan-Shin Lee, Yuh‐Lih Chang,
Tópico(s)Pharmacological Receptor Mechanisms and Effects
ResumoThe emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
Referência(s)